The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: A meta-analysis of individual patient data

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Adjuik, Martin A ^a   Allan, Richard ^b   Anvikar, Anupkumar R ^c   Ashley, Elizabeth A ^d   Ba, Mamadou S ^e   Barennes, Hubert ^f,g   Barnes, Karen I ^h,i   Bassat, Quique ^j,k   Baudin, Elisabeth ^d   Björkman, Anders ^l   Bompart, François ^m   Bonnet, Maryline ^d   Borrmann, Steffen ^n,o   Brasseur, Philippe ^p   Bukirwa, Hasifa ^q   Checchi, Francesco ^d   Cot, Michel ^r,s   Dahal, Prabin ^h,t   D'Alessandro, Umberto ^u,v   Deloron, Philippe ^r,s   Desai, Meghna ^w   Diap, Graciela ^x   Djimde, Abdoulaye ^y   Dorsey, Grant ^z   Doumbo, Ogobara ^y   Espié, Emmanuelle ^aa   Etard, Jean Francois ^d,ab   Fanello, Caterina ^t,ac   Faucher, Jean François ^r,s,ad   Faye, Babacar ^e   Flegg, Jennifer ^h,ae   Gaye, Oumar ^e   Gething, Peter ^af   González, Raquel ^j,k   Grandesso, Francesco ^d   Guerin, Philippe ^h,t   Guthmann, Jean Paul ^d   Hamour, Sally ^ag   Hasugian, Armedy Ronny ^ah   Hay, Simon ^af   Humphreys, Georgina ^h,t   Jullien, Vincent ^s   Juma, Elizabeth ^ai   Kamya, Moses ^aj   Karema, Corine ^ak   Kiechel, Jean ^x   Kremsner, Peter ^n,al   Krishna, Sanjeev ^am   Lameyre, Valérie ^m   Ibrahim, Laminou ^an   Lee, Sue ^t,ac   Lell, Bertrand ^n,al   Martensson, Andreas ^l,ao   Massougbodji, Achille ^ap   Menan, Hervé ^aq   Ménard, Didier ^ar   Menéndez, Clara ^j,k   Meremikwu, Martin ^as   Moreira, Clarissa ^h,t   Nabasumba, Carolyn ^d,at,au   Nambozi, Michael ^e   Ndiaye, Jean Louis ^e   Nikiema, Frederic ^av   Nsanzabana, Christian ^h,t   Ntoumi, Francine ^n,aw   Ogutu, Bernhards ^ax   Olliaro, Piero ^t,ay   Osorio, Lyda ^az   Ouédraogo, Jean Bosco ^f,av   Penali, Louis ^h   Pene, Mbaye ^e   Pinoges, Loretxu ^d   Piola, Patrice ^ba   Price, Ric ^t,bb   Roper, Cally ^bc   Rosenthal, Philip ^z   Rwagacondo, Claude Emile ^bd   Same Ekobo, Albert ^be   Schramm, Birgit ^d   Seck, Amadou ^h   Sharma, Bhawna ^bf   Sibley, Carol Hopkins ^h,bg   Sinou, Véronique ^bh   Sirima, Sodiomon ^bi   Smith, Jeffery ^h,bj   Smithuis, Frank ^bk,bl   Somé, Fabrice A ^av   Sow, Doudou ^e   Staedke, Sarah ^bc,bm   Stepniewska, Kasia ^h   Swarthout, Todd ^bk   Sylla, Khadime ^e   Talisuna, Ambrose ^h,af   Tarning, Joel ^h,t,ac   Taylor, Walter R J ^ay,bn   Temu, Emmanuel ^b,bo,bp   Thwing, Julie ^w   Tjitra, Emiliana ^ah   Tine, Roger C K ^e   Tinto, Halidou ^f,av   Vaillant, Michel ^bq,br   Valecha, Neena ^c   Van den Broek, Ingrid ^bk,bs   White, Nicholas ^t,ac   Yeka, Adoke ^q,aj   Zongo, Issaka ^av   more..

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Ghana)

^b MENTOR Initiative   (United Kingdom)

^c NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^d EPICENTRE   (France)

^e UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^f CENTRE MURAZ   (Burkina Faso)

^g French Foreign Affairs   (France)

^h WorldWide Antimalarial Resistance Network   (Kenya)

ⁱ UNIVERSITY OF CAPE TOWN   (South Africa)

^j Ministérioda Saúde   (Mozambique)

^k UNIVERSITY OF BARCELONA   (Spain)

^l KAROLINSKA INSTITUTE   (Sweden)

^m SANOFI   (France)

ⁿ UNIVERSITY OF TÜBINGEN   (Germany)

^o German Centre for Diabetes Research   (Germany)

^p INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^q Uganda Malaria Surveillance Project   (Uganda)

^r INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^s UNIVERSITÉ PARIS DESCARTES   (France)

^t UNIVERSITY OF OXFORD   (United Kingdom)

^u INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^v Medical Research Council Unit   (Gambia)

^w CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^x Drugs for Neglected Diseases Initiative   (Switzerland)

^y UNIVERSITY OF BAMAKO   (Mali)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa INSTITUT PASTEUR DE DAKAR   (Senegal)

^ab INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^ac MAHIDOL UNIVERSITY   (Thailand)

^ad UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^ae MONASH UNIVERSITY   (Australia)

^af UNIVERSITY OF OXFORD   (United Kingdom)

^ag ROYAL FREE HOSPITAL   (United Kingdom)

^ah NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^ai KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^aj MAKERERE UNIVERSITY   (Uganda)

^ak Ministry of Health   (Rwanda)

^al Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

^am ST GEORGE S HOSPITAL   (United Kingdom)

^an Centre de Recherche Médicale et Sanitaire   (Niger)

^ao UPPSALA UNIVERSITY   (Sweden)

^ap UNIVERSITY OF ABOMEY CALAVI   (Benin)

^aq UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^ar INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^as UNIVERSITY OF CALABAR   (Nigeria)

^at MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^au TROPICAL DISEASES RESEARCH CENTRE   (Zambia)

^av Institut de Recherche en Sciences de la Sante   (Burkina Faso)

^aw Fondation Congolaise pour la Recherche Médicale Faculté des Sciences de la Santé University Marien Ngouabi   (Congo)

^ax WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^ay WORLD HEALTH ORGANIZATION   (Switzerland)

^az CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^ba INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

^bb MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^bc LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^bd UNICEF   (United States)

^be Centre Hospitalier et Universitaire de Yaounde   (Cameroon)

^bf Drugs for Neglected Diseases initiative   (India)

^bg UNIVERSITY OF WASHINGTON   (United States)

^bh AIX MARSEILLE UNIVERSITY   (France)

^bi Burkina Faso   (Burkina Faso)

^bj University of Maryland School of Medicine Center for Vaccine Development   (United States)

^bk MÉDECINS SANS FRONTIÈRES   (Switzerland)

^bl Medical Action Myanmar   (Myanmar)

^bm INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^bn GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^bo SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^bp UNIVERSITY OF BASEL   (Switzerland)

^bq LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^br UNIVERSITÉ DE BORDEAUX   (France)

^bs NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

Amodiaquine; Artesunate; Dosing; Drug resistance; Efficacy; Malaria; Plasmodium falciparum

Indexed keywords

AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DRUG COMBINATION;

AGE; ANEMIA; ARTICLE; BODY WEIGHT; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; GENOTYPING TECHNIQUE; HUMAN; MALARIA FALCIPARUM; META ANALYSIS; NEUTROPENIA; NEUTROPHIL COUNT; PARASITEMIA; VOMITING; AFRICA; DOSE RESPONSE; DRUG COMBINATION; FEMALE; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME;

AFRICA; AMODIAQUINE; ANTIMALARIALS; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84928776445     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0301-z     Document Type: Article

References (82)

1. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J. 2008;7:S8.
2. WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014. p. 242.
3. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc L B Biol Sci. 1999;354:739-49.
4. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;3, CD007483.
5. Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8:203.
6. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007;44:1067-74.
7. Smithuis F, Kyaw MK, Phe O, Win T, Aung PP, Oo APP, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10:673-81.
8. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet. 2002;359:1365-72.
9. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474-80.
10. Bonnet M, Broek I, van Herp M, Urrutia PP, van Overmeir C, Kyomuhendo J, et al. Varying efficacy of artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. Malar J. 2009;8:192.
11. Rwagacondo CE, Karema C, Mugisha V, Erhart A, Dujardin JC, Van Overmeir C, et al. Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health. 2004;9:1091-8.
12. Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen AT, et al. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J Infect Dis. 2006;193:1738-41.
13. Sa JM, Twu O. Protecting the malaria drug arsenal: halting the rise and spread of amodiaquine resistance by monitoring the PfCRT SVMNT type. Malar J. 2010;9:374.
14. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, et al. Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A. 2009;106:18883-9.
15. The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119.
16. Thanh NX, Trung TN, Phong NC, Quang HH, Dai B, Shanks GD, et al. The efficacy and tolerability of artemisinin-piperaquine (Artequick(R)) versus artesunate-amodiaquine (Coarsucam) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J. 2012;11:217.
17. Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, et al. Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health. 2009;14:79-87.
18. Sirima SB, Tiono AB, Gansane A, Diarra A, Ouedraogo A, Konate AT, et al. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J. 2009;8:48.
19. Clinical trials review. http://www.wwarn.org/tools-resources/literature-reviews/wwarn-clinical-trials-publication-library/methodology.
20. WWARN DP Study Group TWARN (WWARN) DS Group: The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013, 10:e1001564. doi:10.1371/journal.pmed.1001564.
21. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.
22. WWARN: Statistical Analysis Plan, AS-AQ Dose Impact Study Group. Version 1.9. WordlWide Antimalarial Resistance Network, Oxford, 2012.
23. WWARN. Clinical Module: Data Management and Statistical Analysis Plan. Version 1.2. WorldWide Antimalarial Resistance Network, Oxford, 2012.
24. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. Stat Med. 2004;23:369-88.
25. Munda M, Legrand C. Adjusting for centre heterogeneity in multicentre clinical trials with a time-to-event outcome. Pharm Stat. 2014;13:145-52.
26. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum. 1953;9:531-41.
27. Guidelines for the treatment of malaria, 2nd ed. http://www.who.int/malaria/publications/atoz/9789241547925/en/
28. Price R, Luxemburger C, van Vugt M, Nosten F, Kham A, Simpson J, et al. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92:207-11.
29. Nacher M, Carrara VI, Ashley E, McGready R, Hutagalung R, Nguen JV, et al. Seasonal variation in hyperparasitaemia and gametocyte carriage in patients with Plasmodium falciparum malaria on the Thai-Burmese border. Trans R Soc Trop Med Hyg. 2004;98:322-8.
30. Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ - a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J. 2009;8:125.
31. Sinou V, Malaika LT, Taudon N, Lwango R, Alegre SS, Bertaux L, et al. Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT) following oral administration in African malaria patients. Eur J Drug Metab Pharmacokinet. 2009;34:133-42.
32. Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar J. 2011;10:237.
33. De la Hoz RF, Porras Ramirez A, Rico Mendoza A, Cordoba F, Rojas DP. Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial. Rev Soc Bras Med Trop. 2012;45:732-8.
34. Espie E, Lima A, Atua B, Dhorda M, Flevaud L, Sompwe EM, et al. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malar J. 2012;11:174.
35. Faye B, Kuete T, Kiki-Barro CP, Tine RC, Nkoa T, Ndiaye JL, et al. Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malar J. 2012;11:433.
36. Anvikar AR, Sharma B, Shahi BH, Tyagi PK, Bose TK, Sharma SK, et al. Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India. Malar J. 2012;11:97.
37. Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, et al. Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar J. 2013;12:53.
38. Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority. Malar J. 2013;12:251.
39. Elliott I, Mayxay M, Yeuichaixong S, Lee SJ, Newton PN. The practice and clinical implications of tablet splitting in international health. Trop Med Int Health. 2014;19:754-60.
40. Taylor W, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, ter Kuile FO. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Organ. 2006;84:956-64.
41. Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004;82:935-9.
42. Amodiaquine PK/PD Study Group. http://www.wwarn.org/working-together/study-groups/amodiaquine-pkpd-study-group
43. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, et al. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011. PLoS One. 2013;8:e64299.
44. Grandesso F, Hagerman A, Kamara S, Lam E, Checchi F, Balkan S, et al. Low efficacy of the combination artesunate plus amodiaquine for uncomplicated falciparum malaria among children under 5 years in Kailahun, Sierra Leone. Trop Med Int Health. 2006;11:1017-21.
45. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005;41:1079-86.
46. Thwing JI, Odero CO, Odhiambo FO, Otieno KO, Kariuki S, Ord R, et al. In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health. 2009;14:294-300.
47. Ochong EO, van den Broek IV, Keus K, Nzila A. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg. 2003;69:184-7.
48. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg. 2006;75:155-61.
49. Echeverry DF, Holmgren G, Murillo C, Higuita JC, Bjorkman A, Gil JP, et al. Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Am J Trop Med Hyg. 2007;77:1034-8.
50. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother. 2007;51:3023-5.
51. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol. 2007;7:562-9.
52. Danquah I, Coulibaly B, Meissner P, Petruschke I, Muller O, Mockenhaupt FP. Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso. Acta Trop. 2010;114:63-6.
53. Dittrich S, Alifrangis M, Stohrer JM, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, et al. Falciparum malaria in the north of Laos: the occurrence and implications of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene haplotype SVMNT. Trop Med Int Health. 2005;10:1267-70.
54. Beshir K, Sutherland CJ, Merinopoulos I, Durrani N, Leslie T, Rowland M, et al. Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrt SVMNT allele at codons 72 to 76. Antimicrob Agents Chemother. 2010;54:3714-6.
55. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006;1:e7.
56. Thanh NX, Trung TN, Phong NC, Thien NX, Dai B, Shanks GD, et al. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Heal. 2009;14:504-11.
57. Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986;1:411-4.
58. Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis. 2008;46:985-91.
59. WWARN AL Study Group TWARNA Dose Impact S Group. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a pooled analysis of individual patient data. Lancet Infect Dis. 2015; In press.
60. WHO List of Prequalified Medicinal Products. http://apps.who.int/prequal/query/ProductRegistry.aspx.
61. Ecker A, Lehane AM, Clain J, Fidock DA. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 2012;28:504-14.
62. Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013;89:1025-38.
63. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50-5.
64. Barennes H, Nagot N, Valea I, Koussoube-Balima T, Ouedraogo A, Sanou T, et al. A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. Trop Med Int Heal. 2004;9:438-44.
65. Bonnet M, Roper C, Félix M, Coulibaly L, Kankolongo GM, Guthmann JP. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré. Malar J. 2007;6:54.
66. Bukirwa H, Critchley J. Sulfadoxine-pyrimethamine plus artesunate versus sulfadoxine-pyrimethamine plus amodiaquine for treating uncomplicated malaria. Cochrane Database Syst Rev. 2006;1, CD004966.
67. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA. 2007;297:2210-9.
68. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis. 2009;200:57-65.
69. Faye B, Offianan AT, Ndiaye JL, Tine RC, Toure W, Djoman K, et al. Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health. 2010;15:608-13.
70. Guthmann JP, Ampuero J, Fortes F, van Overmeir C, Gaboulaud V, Tobback S, et al. Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg. 2005;99:485-92.
71. Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, et al. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg. 2006;75:143-5.
72. Hamour S, Melaku Y, Keus K, Wambugu J, Atkin S, Montgomery J, et al. Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Trans R Soc Trop Med Hyg. 2005;99:548-54.
73. Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR. Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother. 2010;54:2611-7.
74. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006;100:1105-11.
75. Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, et al. Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. Malar J. 2009;8:5.
76. Ménard D, Ratsimbasoa A, Randrianarivelojosia M, Rabarijaona L-P, Raharimalala L, Domarle O, et al. Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: up-dated baseline data from randomized and multi-site clinical trials. Malar J. 2008;7:55.
77. Osorio L, Gonzalez I, Olliaro P, Taylor WR. Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia. Malar J. 2007;6:25.
78. Sagara I, Fofana B, Gaudart J, Sidibe B, Togo A, Toure S, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg. 2012;87:50-6.
79. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet. 2004;364:1950-7.
80. Swarthout TD, van den Broek IV, Kayembe G, Montgomery J, Pota H, Roper C. Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. Trop Med Int Health. 2006;11:1503-11.
81. Van den Broek I, Kitz C, Al Attas S, Libama F, Balasegaram M, Guthmann J-P. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J. 2006;5:113.
82. Yeka A, Banek K, Bakyaita N, Staedke SG, Kamya MR, Talisuna A, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med. 2005;2:e190.